


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 018781-006810US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TO: TOWNSEND and TOWNSEND and CREW LLP

By:



14 April 2003

Malinda Adair

RECEIVED

APR 24 2003

TECHNOLOGY CENTER R3700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

POWERS et al.

Application No.: 10/041,030

Filed: December 28, 2001

For: DIAGNOSIS AND TREATMENT
OF CANCER USING MAMMALIAN
PELLINO POLYPEPTIDES AND
POLYNUCLEOTIDES

Examiner: Not yet assigned

Art Unit: 3736

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

RECEIVED

APR 25 2003

TECH CENTER 1600/2900

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

Also enclosed is a copy of the International Search Report issued in the corresponding PCT application. The references cited herein are all from the PCT Search Report and exclude those cited in our two previously submitted IDS's.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

CERTIFICATION

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,



Jean M. Lockyer, Ph.D.
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JML:mcd

SF 1451462 v1



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 1 of 2

Complete if Known

Application Number	10/041,030
Filing Date	December 28, 2001
First Named Inventor	Powers, Scott, et. al.
Art Unit	3736
Examiner Name	Not yet assigned
Attorney Docket Number	018781-006810US

RECEIVED
APR 24 2003
TECHNOLOGY CENTER R3700**U.S. PATENT DOCUMENTS**

Examiner	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

RECEIVED

APR 25 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	CA	PCT	WO 01/09318	A1	02/08/2001	Helix Research	English abstract only	<input type="checkbox"/>
	CB	PCT	WO 02/21138	A2	03/14/2002	Axaron Bioscience	English abstract only	<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>


Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 2 of 2**Complete if Known**

Application Number	10/041,030
Filing Date	December 28, 2001
First Named Inventor	Powers, Scott, et. al.
Art Unit	3736
Examiner Name	Not yet assigned
Attorney Docket Number	018781-006810US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	CC	Bacher, Susanne, <i>et al.</i> , "The <i>Drosophila</i> proteins Pelle and Tube induce JNK/AP-1 activity in mammalian cells," <i>FEBS Letters</i> (2001) 497: 153-158
	CD	Hotta, Kohji, <i>et al.</i> , "Characterization of Brachyury-Downstream Notochord Gnees in the <i>Ciona intestinalis</i> Embryo," <i>Development Biology</i> (2000) 224: 69-80
	CE	Kennedy, E.J. and Moynagh, P.N., "Pellino related intracellular signaling molecule (Pellino)", (2001) Abstract XP002235786
	CF	Kennedy, E.J. Moynagh, P.N., "PRISM, a novel mediator of Toll/IL-1 signalling,"(2001) Abstract no. XP002211562
	CG	Resch <i>et al.</i> , "Homo sapiens pellino 2 (PELI2) mRNA, complete cds," (2000) Abstract XP002235783
	CH	Resch, K. <i>et al.</i> , "Assignment of homologous genes, <i>Peli 1/PELI1</i> and <i>Peli2/PELI2</i> , for the Pelle adaptor protein Pellino to mouse chromosomes 11 and 14 and human chromosomes 2p13.3 and 14q21, respectively, by physical and radiation hybrid mapping," <i>Cytogenetics and Cell Genetics</i> (2001) 92: 172-174
	CI	Rich, T. <i>et al.</i> , "How low can Toll go?" <i>Trends in Genetics</i> (2000) 16: 292-294
	CJ	Rich, T. <i>et al.</i> , "Pellino-related sequences from <i>Caenorhabditis elegans</i> and <i>Homo sapiens</i> ," <i>Immunogenetics</i> (2000) 52: 145-149
	CK	Ruben, S.M. <i>et al.</i> , "Human colon cancer antigen encoding cDNA SEQ IS NO: 787," (2001) Abstract no. XP002235784
	CL	Ruben, S.M. <i>et al.</i> "Human colon cancer antigen encoding cDNA SEQ ID NO: 1313," (2001) Abstract no. XP002235785

Examiner
SignatureDate
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

SF 1451462 v1